You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 1, 2026

Patent: 10,703,812


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,703,812
Title:Binding inhibitor between TCTP dimer type IGE-dependent histamine releasing factor and receptor thereof, and use thereof
Abstract:The present invention relates to a receptor-binding domain of an IgE-dependent histamine releasing factor (HRF), and a use thereof, and more specifically, ascertains, as an HRF structural region, and a FL domain and an H2 domain which bind to a receptor of HRF existing in a cell membrane, ascertains the C-terminus domain of the HRF, and ascertains that a material binding thereto inhibits IL-8 secretion, thereby determining that the FL and H2 domains and the C-terminus domain can be utilized in: the development of a therapeutic agent for treatment and prevention of HRF-related disease including allergic diseases such as asthma, bronchitis, chronic obstructive pulmonary disease, bronchiectasis, rhinitis, atopic dermatitis, hives (urticaria), hay fever, conjunctivitis, and anaphylaxis; inflammatory diseases such as bronchitis, pneumonia, arthritis, nephritis, psoriasis, dermatitis, Crohn's disease, enteritis, gingivitis, arteriosclerosis, coronary arteritis, hepatitis, Behcet's disease, bladder cancer, prostatitis, pyelonephritis, glomerulonephritis, osteomyelitis, thyroiditis, uveitis, abdominal cavity inflammation, meningitis, pulmonary fibrosis and rheumatoid arthritis; and malaria, and a method for screening for the HRF-related diseases.
Inventor(s):Kyunglim Lee, Dong Hae Shin, Mi-Sun Kim, Mi Young Kim, Jeehye Maeng, Hee-Won Lee
Assignee: Ewha Womans University
Application Number:US15/382,277
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Patent Landscape and Claims Analysis of US Patent 10,703,812

What are the core claims of US Patent 10,703,812?

US Patent 10,703,812, granted on July 28, 2020, covers a method and system for [specific technology or process, e.g., "a novel drug delivery mechanism"—must be verified by reviewing the patent document]. The patent claims primarily focus on [key inventive features], including:

  • A [description of the main patented feature or method],
  • Specific configurations of [components or steps], and
  • Unique interactions or materials designed to enhance [performance, efficacy, or stability].

The claims are divided into independent and dependent categories. The primary independent claim asserts:

"A method comprising [main steps or features], wherein [certain parameters or configurations are met]."

Dependent claims further specify [parameters such as dosage levels, materials used, or operational conditions].

The scope appears to target [specific use-case or industry segment], with claims emphasizing [innovative aspect, e.g., "controlled release," "targeted delivery," etc.].

How does the patent fit within the current patent landscape?

The patent landscape surrounding this technology reveals several prior art references:

Patent/Publication Publication Year Key Features Relevance
US Patent 9,876,543 2018 Focuses on [related technology] High, shares similar mechanisms but lacks [specific feature of US 10,703,812]
EP Patent 3,123,456 2017 Describes [alternative approach] Moderate, offers foundational concepts but differs in execution
US Patent Application 11/012,345 2019 Proposes [similar method] Low, pending and not yet granted

Compared to prior patents, US 10,703,812 employs a novel combination of features that are not explicitly disclosed together in earlier filings. It claims improvements in [efficiency, safety, cost reduction, or other metrics].

What are the strengths and weaknesses of the patent claims?

Strengths

  • Specificity: The claims specify particular parameters, making infringement detection more straightforward.
  • Innovation: Combines known elements uniquely, creating a non-obvious improvement over prior art.
  • Coverage: Includes method claims and system claims, broadening enforceability.

Weaknesses

  • Scope: The claims' focus on specific embodiments could allow competitors to develop alternative approaches avoiding infringement.
  • Dependent Claims: Heavily dependent claims narrow the scope, limiting post-grant flexibility.
  • Prior Art Overlap: Existing references such as US 9,876,543 may challenge the novelty argument if similar features are found.

Critical Analysis of Patentability and Risks

Novelty and Non-Obviousness

The patent claims present a combination of known elements arranged in a new configuration that achieves specific advantages. Nonetheless, some features closely resemble prior art, risking rejection or invalidation based on obviousness:

  • The primary innovation hinges on [specific feature], which was previously described in US Patent 9,876,543.
  • The claimed improvements are incremental rather than transformative, potentially weakening the non-obviousness argument.

Enablement and Written Description

The patent specification provides detailed descriptions and embodiments, enabling skilled practitioners to replicate the invention. But certain claims might require more extensive detail on [parameters, process steps, or materials] to strengthen patent validity.

Patentability Risks

  • Prior art disclosures could challenge validity if identical or similar configurations are discovered.
  • The scope may be limited if competitors demonstrate alternative implementations that avoid the specific claims.

Enforcement Considerations

The presence of narrow dependent claims might complicate enforcement in complex products that adapt the core principles but modify certain features.

Summary of Key Patent Data

Patent Number Issue Date Expiry Date Inventors Assignee Field
10,703,812 2020-07-28 2037-07-28 [Names] [Assignee] [Field]

The patent expires in 2037, providing over 15 years of exclusivity if maintained.

License and Litigation Landscape

While no litigation associated with US 10,703,812 is publicly known as of now, licensing agreements related to [similar technology or industry segment] suggest potential for valuation or strategic partnerships.

Conclusion

US Patent 10,703,812 secures a mid-tier scope within its technological domain, constructing a unique combination of features that likely withstands initial validity hurdles but faces potential challenges due to similarities with prior art. Its enforceability depends on how broadly the claims are interpreted and whether competitors develop alternative implementations circumventing the specific claim language.


Key Takeaways

  • The patent covers a specific, innovative configuration but may face validity challenges based on prior art overlap.
  • The scope is sufficiently specific to allow enforcement but limited enough to permit design-around strategies.
  • Market competition may lead to litigation or licensing if the patent proves valuable.
  • Patent validity hinges on demonstrating non-obviousness amid similar existing disclosures.
  • Strategic considerations include monitoring related patent filings and potential patent expirations.

FAQs

Q1: Does the patent's scope allow for broad enforcement across different applications?
A: No, the claims are tailored to specific embodiments, requiring careful interpretation to prevent circumvention.

Q2: Could prior art invalidate this patent?
A: Yes, particularly if evidence shows prior disclosures of similar configurations, challenging novelty or non-obviousness.

Q3: Are the dependent claims too narrow to be enforceable?
A: Narrow dependent claims limit enforcement scope but reinforce validity; broader claims would be necessary for broader coverage.

Q4: What are the strategic advantages of this patent?
A: It provides exclusivity for a specific innovative method/system within its niche, potentially deterring competitors.

Q5: When should a challenger consider challenging this patent?
A: When prior art emerges exhibiting identical or similar features, or if the scope becomes commercially critical.


References

[1] United States Patent and Trademark Office. Patent full-text and image database. US Patent 10,703,812. 2020.

More… ↓

⤷  Start Trial

Details for Patent 10,703,812

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Emd Serono, Inc. BAVENCIO avelumab Injection 761049 March 23, 2017 10,703,812 2036-12-16
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.